Influence of scalp block on oncological outcomes of high-grade glioma in adult patients with and without isocitrate dehydrogenase-1 mutation

被引:2
|
作者
Sung, Chao-Hsien [1 ]
Tsuang, Fon-Yih [2 ]
Lin, Chih-Peng [3 ]
Chan, Kuang-Cheng [3 ]
Chou, Wei-Han [3 ]
Wu, Chun-Yu [3 ]
机构
[1] Fu Jen Catholic Univ, Fu Jen Catholic Univ Hosp, Dept Anesthesiol, New Taipei, Taiwan
[2] Natl Taiwan Univ Hosp, Dept Neurosurg, Taipei, Taiwan
[3] Natl Taiwan Univ Hosp, Dept Anesthesiol, 7 Chung Shan S Rd, Taipei, Taiwan
关键词
CENTRAL-NERVOUS-SYSTEM; CANCER RECURRENCE; GLIOBLASTOMA; CELL; ANESTHESIA; SURVIVAL; CATECHOLAMINES; CYTOTOXICITY; PROPOFOL; SURGERY;
D O I
10.1038/s41598-021-95851-5
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
High-grade gliomas are notorious for a high recurrence rate even after curative resection surgery. Studies regarding the influence of scalp block on high-grade gliomas have been inconclusive, possibly because the condition's most important genetic mutation profile, namely the isocitrate dehydrogenase 1 (IDH1) mutation, had not been analyzed. Therefore, we conducted a single-center study including patients with high-grade glioma who underwent tumor resection between January 2014 and December 2019. Kaplan-Meier survival analysis revealed that scalp block was associated with longer progression-free survival (PFS; 15.17 vs. 10.77 months, p = 0.0018), as was the IDH1 mutation (37.37 vs. 10.90 months, p = 0.0149). Multivariate Cox regression analysis revealed that scalp block (hazard ratio: 0.436, 95% confidence interval: 0.236-0.807, p = 0.0082), gross total resection (hazard ratio: 0.405, 95% confidence interval: 0.227-0.721, p = 0.0021), and IDH1 mutation (hazard ratio: 0.304, 95% confidence interval: 0.118-0.784, p = 0.0138) were associated with better PFS. Our results demonstrate that application of scalp block, regardless of IDH1 profile, is an independent factor associated with longer PFS for patients with high-grade glioma.
引用
收藏
页数:9
相关论文
共 50 条
  • [21] An incidental finding of a high-grade glioma with pleomorphic and pseudopapillary features (HPAP) with PBRM1 mutation
    Gubbiotti, Maria A.
    Weinberg, Jeffrey S.
    Weathers, Shiao-Pei
    Dasgupta, Pushan
    Tom, Martin C.
    Aldape, Kenneth
    Quezado, Martha
    Abdullaev, Zied
    Huse, Jason T.
    Ballester, Leomar Y.
    JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY, 2024, 83 (02) : 139 - 141
  • [22] A phase 1 trial of intravenous liposomal irinotecan in patients with recurrent high-grade glioma
    Jennifer L. Clarke
    Annette M. Molinaro
    Juan R. Cabrera
    Ashley A. DeSilva
    Jane E. Rabbitt
    Joshua Prey
    Daryl C. Drummond
    Jaeyeon Kim
    Charles Noble
    Jonathan B. Fitzgerald
    Susan M. Chang
    Nicholas A. Butowski
    Jennie W. Taylor
    John W. Park
    Michael D. Prados
    Cancer Chemotherapy and Pharmacology, 2017, 79 : 603 - 610
  • [23] Altered galectin-1 serum levels in patients diagnosed with high-grade glioma
    Verschuere, Tina
    Van Woensel, Matthias
    Fieuws, Steffen
    Lefranc, Florence
    Mathieu, Veronique
    Kiss, Robert
    Van Gool, Stefaan W.
    De Vleeschouwer, Steven
    JOURNAL OF NEURO-ONCOLOGY, 2013, 115 (01) : 9 - 17
  • [24] Altered galectin-1 serum levels in patients diagnosed with high-grade glioma
    Tina Verschuere
    Matthias Van Woensel
    Steffen Fieuws
    Florence Lefranc
    Veronique Mathieu
    Robert Kiss
    Stefaan W. Van Gool
    Steven De Vleeschouwer
    Journal of Neuro-Oncology, 2013, 115 : 9 - 17
  • [25] A phase 1 trial of intravenous liposomal irinotecan in patients with recurrent high-grade glioma
    Clarke, Jennifer L.
    Molinaro, Annette M.
    Cabrera, Juan R.
    DeSilva, Ashley A.
    Rabbitt, Jane E.
    Prey, Joshua
    Drummond, Daryl C.
    Kim, Jaeyeon
    Noble, Charles
    Fitzgerald, Jonathan B.
    Chang, Susan M.
    Butowski, Nicholas A.
    Taylor, Jennie W.
    Park, John W.
    Prados, Michael D.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2017, 79 (03) : 603 - 610
  • [26] Glioma-related epilepsy in patients with diffuse high-grade glioma after the 2016 WHO update: seizure characteristics, risk factors, and clinical outcomes
    Li, Lianwang
    Fang, Shengyu
    Li, Guanzhang
    Zhang, Kenan
    Huang, Ruoyu
    Wang, Yinyan
    Zhang, Chuanbao
    Li, Yiming
    Zhang, Wei
    Zhang, Zhong
    Jin, Qiang
    Zhou, Dabiao
    Fan, Xing
    Jiang, Tao
    JOURNAL OF NEUROSURGERY, 2022, 136 (01) : 67 - 75
  • [27] Functional reorganization of contralesional networks varies according to isocitrate dehydrogenase 1 mutation status in patients with left frontal lobe glioma
    Qi, Chong
    Wang, Rui
    Meng, Lanxi
    Li, Shaowu
    Li, Yiming
    NEURORADIOLOGY, 2022, 64 (09) : 1819 - 1828
  • [28] A Rare High-Grade Glioma with a Histone H3 K27M Mutation in the Hypothalamus of an Adult Patient
    He, Pin
    Chen, Wei
    Qiu, Xi Xiong
    Xi, Yi Bin
    Guan, Hong
    Xia, Jun
    WORLD NEUROSURGERY, 2019, 128 : 527 - 531
  • [29] Oncological outcomes of high-grade T1 non-muscle-invasive bladder cancer treatment in octogenarians
    Aleksander Ślusarczyk
    Karolina Garbas
    Piotr Zapała
    Łukasz Zapała
    Piotr Radziszewski
    International Urology and Nephrology, 2021, 53 : 1591 - 1597
  • [30] Oncological outcomes of high-grade T1 non-muscle-invasive bladder cancer treatment in octogenarians
    Slusarczyk, Aleksander
    Garbas, Karolina
    Zapala, Piotr
    Zapala, Lukasz
    Radziszewski, Piotr
    INTERNATIONAL UROLOGY AND NEPHROLOGY, 2021, 53 (08) : 1591 - 1597